戻る
Lexicon Pharmaceuticals Inc (LXRX)価格
LXRX 株価推移チャート
LXRX 収入
Lexicon Pharmaceuticals Inc
$1.31
-4.37%
$-0.06
終値： Jan 20, 16:00:00 GMT-5
$1.29
-1.52%
$-0.02
アフターマーケット：Jan 20, 20:00:00 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-06
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
LXRXの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Lexicon Pharmaceuticals Inc LXRXの前四半期の収益はどうでしたか？
Lexicon Pharmaceuticals Incの収益見積もりはいくらですか？
Lexicon Pharmaceuticals Incの収益品質スコアはどれくらいですか？
Lexicon Pharmaceuticals Incはいつ収益を報告しますか？
Lexicon Pharmaceuticals Incの予想収益はいくらですか？
Lexicon Pharmaceuticals Incは収益予想を上回りましたか？
主要データ
前終値
$1.37
始値
$1.33
当日レンジ
$1.24 - $1.33
52週レンジ
$0.28 - $1.66
取引高
1.6M
平均取引高
1.7M
1株当たり利益(TTM)
-0.19
配当利回り
--
時価総額
$468.7M
LXRXとは何ですか？
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The company is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The company has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. The company is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. The company is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.